Tesamorelin
Support your body's natural growth hormone rhythm.
Vial content, not a dose.
Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone — the full 44-amino-acid GHRH sequence, carrying a trans-3-hexenoic acid group at its N-terminus. That single structural addition is the point: it resists the enzyme DPP-IV, which would otherwise break the native hormone down quickly. Tesamorelin does not supply growth hormone. It carries the same instruction the hypothalamus already sends to the pituitary, in a form built to survive long enough to deliver it.
Growth hormone release was never meant to be a constant supply — the hypothalamus sends GHRH in pulses, and the pituitary answers in kind. Tesamorelin binds that same receptor and leaves the rhythm intact. Nothing is overridden and nothing is replaced; the original instruction is simply carried to the gland that has always known how to respond to it.
How the signal travels.
Tesamorelin acts one step upstream of growth hormone itself, on the GHRH signaling path that runs from hypothalamus to pituitary. Four structural and receptor-level details explain how that instruction survives and where it lands.
The trans-3-hexenoic acid modification at the N-terminus shields the 44-amino-acid chain from DPP-IV, the enzyme that rapidly clears native GHRH. The signal stays intact on its way to the pituitary.
Tesamorelin binds the GHRH receptor on pituitary somatotrophs — the same receptor the body's own hypothalamic GHRH occupies. No new pathway is introduced; an existing one is engaged.
Receptor engagement stimulates the somatotroph to release growth hormone the body has produced itself. Nothing exogenous is administered — the gland supplies the hormone, prompted rather than bypassed.
Because release originates at the pituitary rather than from an outside supply, the natural pulsatile pattern of growth hormone secretion is preserved rather than flattened into continuous exposure.
What it's used to support.
Tesamorelin is of interest to women 35 and older who are noticing changes in body composition — particularly abdominal fat distribution — alongside the broader hormonal shifts of this stage, and who would rather support the gland that regulates growth hormone than supply the hormone directly. It belongs inside a supervised protocol, not on its own.
The figures above are the amount of lyophilized peptide in the vial — they are not a dose. Your protocol, timing, and duration are set one-to-one with a licensed practitioner based on your history and goals.
The specifics, if you want them.
Technical specifications
Where the research stands
Tesamorelin has been studied in a large-scale Phase 3 clinical program, which is more human evidence than most peptides carry. That work was conducted in a narrow population — adults with HIV-associated lipodystrophy — and examined visceral fat in that context. Its relevance to general body composition in women has not been established to the same standard.
Storage & handling
Before you start.
Tesamorelin is prepared from a lyophilized vial containing 10 mg — that figure is the vial content, not a dose. We don't publish a standard protocol, because route, amount, and schedule depend on your history, your labs, and what else is already part of your care. All of it is confirmed with a licensed practitioner during consultation.
We won't promise one. Growth hormone signaling is a rhythm rather than a switch, and response depends on your baseline output, age, and the rest of the protocol built around you. Your practitioner can name the markers that matter in your case and decide when to look at them again.
Yes. Tesamorelin acts directly on the growth hormone axis at the level of the pituitary, which means it should only be introduced by a licensed practitioner who can review your health history, your current medications, and your hormonal picture, and then decide whether it belongs in your protocol at all.
Growth hormone given directly bypasses the pituitary and arrives as a continuous outside supply. Tesamorelin works one step earlier: it binds the GHRH receptor on the pituitary, and the gland releases its own growth hormone in its own pulsatile pattern. The rhythm stays the body's, which is the distinction that matters here.
It covers a specific population. The Phase 3 work was carried out in adults with HIV-associated lipodystrophy and looked at visceral fat in that setting. That is real, controlled human research, and it is also narrower than the way this compound is often discussed. We'd rather you know the difference before you consider it.
Every Inner Peptides formula is independently tested before it ships, with a Certificate of Analysis available on request. Learn more about our testing standard.
